Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2015—Microbiologics is expanding its line of Helix Elite Molecular Standards with two product formats: inactivated extraction controls and genomic DNA extracts. Used for validation, verification, proficiency testing, and quality control of molecular assays, Inactivated and Genomic Extract controls are available in multiple strains; the first genomic extracts are from low passage mycoplasma strains sourced from the National Collection of Type Cultures.
July 2015—The patented PrestoChill is an all-dry cryoembedding system from Milestone Medical that does not use liquid nitrogen, CO2, or isopentane. The 60-second freezing time prevents the formation of ice crystals. An automatic defrost cycle is provided to eliminate the potential formation of ice on the freezing platform.
July 2015—Rheonix showcased in June its Encompass Optimum research-use-only platform at the 115th General Meeting of the American Society for Microbiology. The Encompass Optimum is an automated system for building and implementing molecular assays as a nonclinical tool.
July 2015—The journal Lung Cancer published a paper demonstrating the economic implications to the U.S. health care system of using VeriStrat in guiding treatment of patients with advanced non-small cell lung cancer. The paper’s authors conclude that using Biodesix’s VeriStrat improves overall survival and decreases medical costs in the U.S. payer system.
July 2015—Qiagen launched two Investigator STR assay kits for analysis of DNA evidence in forensic laboratories in the United States—the Investigator 24plex QS Kit for amplification of the CODIS core and European Standard Set marker sets from casework samples and the Investigator 24plex GO! Kit for direct amplification of the CODIS core and ESS marker sets from reference samples.
July 2015—Eppendorf has added two screw-cap tubes in 15 mL and 50 mL sizes to its line of Eppendorf Tubes. The newly designed screw caps provide optimal sealing properties, and their grooved and multisurface side contour provide a secure, slip-free grip.
July 2015—Enzo’s TIMP-1 ELISA kit is designed to provide a useful tool for investigating the TIMP-1 levels in multiple human matrices and aims to advance the studies on TIMP-1 function. The assay format allows for quantitative detection of 30 pg/mL of TIMP-1 in various sample types including serum, plasma, saliva, urine, and tissue culture media.
July 2015—Euroimmun US announced the FDA 510(k) clearance of its EuroPattern System, which consists of a fluorescent microscope (oculars included for manual interpretation) and software that acquires, interprets, archives, and displays digital images of stained IFA slides.
July 2015—Biocartis presented liquid biopsy data from the company’s BRAF mutation study at the American Society of Clinical Oncology annual meeting in June. The study, in collaboration with Bart Neyns, MD, PhD, University Hospital Brussels, showed that BRAF oncogene mutations monitored in plasma from metastatic melanoma patients on Biocartis’ Idylla system were significantly associated with treatment response and progression.
June 2015—Horizon Discovery Group and ArcherDX have signed an original equipment manufacturer agreement in which Horizon’s reference materials will be supplied as a standalone product alongside ArcherDX’s Archer FusionPlex to aid customer validation of its ALK fusion assay kits. The ALK fusion tests can run on both Illumina and Ion Torrent next-generation sequencing platforms.
